Judith Profant, PhD, MS

Development of JZP-258, a Low-Sodium Formulation of Oxybate for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy

Narcolepsy is a lifelong neurologic disorder characterized by excessive daytime sleepiness (EDS), cataplexy, disrupted nighttime sleep (DNS), sleep-related hallucinations, and sleep paral...

Gunjan Junnarkar , PhD;

Judith Profant , PhD, MS;

Jed Black , MD;

Teresa Steininger , PhD;

Roman Skowronski , MD, PhD;

10/08/2020

Challenges and Considerations in Design of a Placebo-Controlled, Double-Blind, Randomized-Withdrawal Study Evaluating the Efficacy and Safety of JZP-258 for the Treatment of Idiopathic Hypersomnia

No treatment is approved for idiopathic hypersomnia (IH). A retrospective chart review (Leu-Semenescu, et al. Sleep Med. 2016;17:38-44) demonstrated effectiveness of sodium oxybate (SXB) ...

Patricia Chandler , MD;

Dandan Chen , MD, PhD;

Judith Profant , PhD, MS;

Amanda Sterkel , PhD;

Yves Dauvilliers , MD, PhD;

10/08/2020

Long-Term Safety and Efficacy of Sodium Oxybate in Pediatric Patients With Narcolepsy: Evaluation of Depression, Anxiety, and Suicidal Risk

Introduction: Narcolepsy primarily begins in childhood/adolescence. Sodium oxybate (SXB) was evaluated as a treatment for narcolepsy in children/adolescents in a placebo-controlled, rando...

Emmanuel Mignot , MD, PhD;

Michael Strunc , MD;

Judith Profant , PhD, MS;

Y. Grace Wang , MD;

Rupa Parvataneni , MS;

Jed Black , MD;

03/01/2019

Antidepressant, Stimulant/Wake Promoting Agent, and Sedative/Hypnotic Use in Patients with Obstructive Sleep Apnea in the United States

OBJECTIVE: To assess the use of antidepressants, stimulants (amphetamine/methylphenidate), wake promoting agents (WPAs; modafinil/armodafinil), and sedative/hypnotics in patients with obs...

Maurice Ohayon , MD, DSc, PhD;

Susan Gibson , RPh, MBA;

Brian Scheckner , PharmD;

Cristina Milesi , PhD;

Judith Profant , PhD, MS;

03/01/2019